Stryker stock faces lower outlook after third-quarter miss

Stryker reported third-quarter results on Thursday, October 29, with sales growth but a lower full-year outlook. The medical technology company said performance fell short of its own expectations, while Chief Executive Kevin Lobo said the underlying fundamentals remained strong. The company's third-quarter release was issued after the U.S. market close.

Stryker generated net sales of USD 6.52 billion in the quarter ended September 30, up 7.7% from a year earlier. Organic sales also increased 7.7%, driven mainly by higher unit volume. MedSurg and Neurotechnology grew 9.2%, while Orthopaedics advanced 5.7% on a reported basis.

Quarterly results and revised outlook

Reported net earnings fell 12.3% to USD 753 million, and diluted earnings per share declined 11.7% to USD 1.96. The release attributes the reported figures to a range of acquisition, integration, structural, regulatory, legal and impairment items. A USD 293 million goodwill impairment was included in the quarter.

On an adjusted basis, net earnings increased 10.1% to USD 1.4 billion and adjusted earnings per share rose 10.3% to USD 3.52. Adjusted operating margin widened by 60 basis points to 26.2%, showing that cost control and operating efficiencies partly offset the pressure visible in the reported figures.

Management now expects 2026 organic sales growth of 6.5% to 7.0%, compared with the previous range of 8.3% to 9.3%. Adjusted diluted earnings per share are forecast at USD 14.80 to USD 14.90, below the prior range of USD 14.95 to USD 15.10. The company expects a modestly positive pricing effect and a slightly favorable currency contribution if exchange rates remain near current levels.

Lobo described the quarter as good in absolute terms but below expectations. He also pointed to a solid fourth quarter and momentum into 2027. The company said fourth-quarter organic growth should be broadly comparable with the third quarter, leaving demand and execution as the main near-term tests for investors.

Stock context for investors

Stryker stock traded at EUR 259.30 on Lang & Schwarz at 12:28 CET on Monday, November 2, 2026, 1.03% below the Xetra close of Friday, October 30, at EUR 262.00. The comparison reflects the latest available Xetra session before the current Monday trading day.

The revised outlook shifts attention from Stryker's margin resilience to the pace at which procedure volumes and operating execution recover. The stronger adjusted margin and earnings growth provide support, but the lower sales and earnings ranges raise the bar for a convincing fourth quarter.

Investors can follow the real-time quote of Stryker stock for the latest trading indication.

The broader U.S. market context is available in the current market reports.

More company-specific developments are available in more news and analyses on Stryker stock.